Currently, there are 190.04M common shares owned by the public and among those 155.23M shares have been available to trade.
The company’s stock has a 5-day price change of 6.55% and 0.30% over the past three months. BBIO shares are trading 32.73% year to date (YTD), with the 12-month market performance up to 49.69% higher. It has a 12-month low price of $21.62 and touched a high of $39.47 over the same period. BBIO has an average intraday trading volume of 2.96 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.55%, 6.70%, and 24.97% respectively.
Institutional ownership of BridgeBio Pharma Inc (NASDAQ: BBIO) shares accounts for 76.85% of the company’s 190.04M shares outstanding.
It has a market capitalization of $6.91B and a beta (3y monthly) value of 1.16. The earnings-per-share (ttm) stands at -$2.85. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.17% over the week and 6.14% over the month.
Earnings per share for the fiscal year are expected to decrease by -18.01%, and 32.14% over the next financial year.
Looking at the support for the BBIO, a number of firms have released research notes about the stock. Redburn Atlantic stated their Buy rating for the stock in a research note on March 31, 2025, with the firm’s price target at $50. Oppenheimer was of a view on October 03, 2024 that the stock is Perform, while Piper Sandler gave the stock Overweight rating on September 04, 2024, issuing a price target of $46. Raymond James on their part issued Outperform rating on March 21, 2024.
